Search

Your search keyword '"Recher, C"' showing total 426 results
Start Over Author "Recher, C"
426 results on '"Recher, C"'

57. S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

Author

Angenendt, L., primary, Röllig, C., additional, Montesinos, P., additional, Martínez-Cuadrón, D., additional, Barragan, E., additional, García, R., additional, Botella, C., additional, Martínez, P., additional, Ravandi, F., additional, Kadia, T., additional, Kantarjian, H.M., additional, Cortes, J., additional, Juliusson, G., additional, Lazarevic, V., additional, Höglund, M., additional, Lehmann, S., additional, Recher, C., additional, Pigneux, A., additional, Bertoli, S., additional, Dumas, P.-Y., additional, Dombret, H., additional, Preudhomme, C., additional, Micol, J.-B., additional, Terré, C., additional, Ráčil, Z., additional, Novák, J., additional, Žák, P., additional, Wei, A.H., additional, Tiong, I.S., additional, Wall, M., additional, Estey, E., additional, Shaw, C., additional, Exeler, R., additional, Wagenführ, L., additional, Stölzel, F., additional, Thiede, C., additional, Stelljes, M., additional, Lenz, G., additional, Mikesch, J.-H., additional, Serve, H., additional, Ehninger, G., additional, Berdel, W.E., additional, Kramer, M., additional, Krug, U., additional, and Schliemann, C., additional

Published
2019
Full Text
View/download PDF

58. PF251 GILTERITINIB PROLONGS SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML WHO HAVE COMMON AML CO-MUTATIONS OR A HIGH FLT3-ITD ALLELIC RATIO

Author

Levis, M., primary, Perl, A., additional, Martinelli, G., additional, Cortes, J., additional, Neubauer, A., additional, Berman, E., additional, Montesinos, P., additional, Baer, M., additional, Larson, R., additional, Chou, W.-C., additional, Yokoyama, H., additional, Recher, C., additional, Yoon, S.-S., additional, Hill, J., additional, Rosales, M., additional, Liu, C., additional, and Bahceci, E., additional

Published
2019
Full Text
View/download PDF

59. PS1041 TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH IDH2-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA – A FRENCH MEDICAL CHART REVIEW ANALYSIS

Author

Pigneux, A., primary, Quesnel, B., additional, Thomas, X., additional, Legrand, O., additional, Botton, S. de, additional, Recher, C., additional, Chantepie, S., additional, Hunault-Berger, M., additional, Nehme, S. Abi, additional, Frattini, M., additional, Tosolini, A., additional, Marion-Gallois, R., additional, Wang, J.J., additional, Reitan, J.F., additional, and Boissel, N., additional

Published
2019
Full Text
View/download PDF

60. PF263 DEEP RESPONSE AFTER CPX-351 TREATMENT IN T-AML AND MRC-AML: A REPORT FROM A MULTICENTRIC FRENCH COHORT

Author

Chiche, E., primary, Bertoli, S., additional, Recher, C., additional, Thomas, X., additional, Loschi, M., additional, Bonmati, C., additional, Roth-Guepin, G., additional, Peterlin, P., additional, Chevallier, P., additional, Lejeune, C., additional, Sauvezie, M., additional, Pigneux, A., additional, Sebert, M., additional, Ades, L., additional, and Cluzeau, T., additional

Published
2019
Full Text
View/download PDF

61. S876 GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL

Author

Perl, A., primary, Martinelli, G., additional, Cortes, J., additional, Neubauer, A., additional, Berman, E., additional, Paolini, S., additional, Montesinos, P., additional, Baer, M., additional, Larson, R., additional, Ustun, C., additional, Fabbiano, F., additional, Di Stasi, A., additional, Stuart, R., additional, Olin, R., additional, Kasner, M., additional, Ciceri, F., additional, Chou, W.-C., additional, Podoltsev, N., additional, Recher, C., additional, Yokoyama, H., additional, Hosono, N., additional, Yoon, S.-S., additional, Lee, J.-H., additional, Pardee, T., additional, Fathi, A., additional, Liu, C., additional, Liu, X., additional, Bahceci, E., additional, and Levis, M., additional

Published
2019
Full Text
View/download PDF

67. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Author

Seymour, JF, Doehner, H, Butrym, A, Wierzbowska, A, Selleslag, D, Jang, JH, Kumar, R, Cavenagh, J, Schuh, AC, Candoni, A, Recher, C, Sandhu, I, del Castillo, TB, Al-Ali, HK, Falantes, J, Stone, RM, Minden, MD, Weaver, J, Songer, S, Beach, CL, Dombret, H, Seymour, JF, Doehner, H, Butrym, A, Wierzbowska, A, Selleslag, D, Jang, JH, Kumar, R, Cavenagh, J, Schuh, AC, Candoni, A, Recher, C, Sandhu, I, del Castillo, TB, Al-Ali, HK, Falantes, J, Stone, RM, Minden, MD, Weaver, J, Songer, S, Beach, CL, and Dombret, H

Abstract

BACKGROUND: Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥65 years) patients in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC. METHODS: We compared clinical outcomes for patients with AML-MRC treated with azacitidine or conventional care regimens (CCR; induction chemotherapy, low-dose cytarabine, or supportive care only) overall and within patient subgroups defined by cytogenetic risk (intermediate or poor) and age (65-74 years or ≥75 years). The same analyses were used to compare azacitidine with low-dose cytarabine in patients who had been preselected to low-dose cytarabine before they were randomized to receive azacitidine or CCR (ie, low-dose cytarabine). RESULTS: Median overall survival was significantly prolonged with azacitidine (n = 129) versus CCR (n = 133): 8.9 versus 4.9 months (hazard ratio 0.74, [95%CI 0.57, 0.97]). Among patients with intermediate-risk cytogenetics, median overall survival with azacitidine was 16.4 months, and with CCR was 8.9 months (hazard ratio 0.73 [95%CI 0.48, 1.10]). Median overall survival was significantly improved for patients ages 65-74 years treated with azacitidine compared with those who received CCR (14.2 versus 7.3 months, respectively; hazard ratio 0.64 [95%CI 0.42, 0.97]). Within the subgroup of patients preselected to low-dose cytarabine before randomization, median overall survival with azacitidine was 9.5 months versus 4.6 months with low-dose cytarabine (hazard ratio 0.77 [95%CI 0.55, 1.09]). Within the low-dose cytarabine preselection group, patients with intermediate-risk cytogenetics who received azacitidine had a median overall survival of 14.1 months versus 6.4 months with low-dose cytarabine, and patients aged 65-74 years had median surviv

Published
2017

68. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)

Author

Millon, L., primary, Herbrecht, R., additional, Grenouillet, F., additional, Morio, F., additional, Alanio, A., additional, Letscher-Bru, V., additional, Cassaing, S., additional, Chouaki, T., additional, Kauffmann-Lacroix, C., additional, Poirier, P., additional, Toubas, D., additional, Augereau, O., additional, Rocchi, S., additional, Garcia-Hermoso, D., additional, Bretagne, S., additional, Dupont, H., additional, Marolleau, J.P., additional, Totet, A., additional, Damiani, C., additional, Berceanu, A., additional, Larosa, F., additional, Bonhomme, J., additional, Chabrot, C., additional, Bouteille, B., additional, Boutoille, D., additional, Gastinne, T., additional, Peterlin, P., additional, Gari Toussaint, M., additional, Poisson, D., additional, Briet, D., additional, Buret, J., additional, Legrand, M., additional, Denis, B., additional, Raffoux, E., additional, Bergeron, A., additional, Veinstein, A., additional, Godet, C., additional, N'guyen, Y., additional, Diallo, S., additional, Sabou, M., additional, Denis, J., additional, Ledoux, M.P., additional, Recher, C., additional, Ruiz, J., additional, Desoubeaux, G., additional, Bailly, E., additional, Chachaty, E., additional, Dromer, F., additional, Lortholary, O., additional, Sitbon, K., additional, and Hoinard, D., additional

Published
2016
Full Text
View/download PDF

73. Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis

Author

Bulai Livideanu, C., primary, Apoil, P. A., additional, Lepage, B., additional, Eischen, M., additional, Laurent, C., additional, Laharrague, P., additional, Lamant, L., additional, Tournier, E., additional, Tavitian, S., additional, Pouplard, C., additional, Recher, C., additional, Laroche, M., additional, Mailhol, C., additional, Dubreuil, P., additional, Hermine, O., additional, Blancher, A., additional, and Paul, C., additional

Published
2015
Full Text
View/download PDF

79. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

Author

Boissel, N., primary, Renneville, A., additional, Leguay, T., additional, Lefebvre, P. C., additional, Recher, C., additional, Lecerf, T., additional, Delabesse, E., additional, Berthon, C., additional, Blanchet, O., additional, Prebet, T., additional, Pautas, C., additional, Chevallier, P., additional, Lepretre, S., additional, Girault, S., additional, Bonmati, C., additional, Guieze, R., additional, Himberlin, C., additional, Randriamalala, E., additional, Preudhomme, C., additional, Jourdan, E., additional, Dombret, H., additional, and Ifrah, N., additional

Published
2015
Full Text
View/download PDF

81. Autologus stern celle transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloisdosis : results of the French multicentric randomized trial (MAG and IFM intergroup)

Author

Jaccard, Arnaud, Moreau, P., Leblond, V., Leleu, X., Bennoubker, L, Hermine, O., Recher, C., Malphette, M, Lioure, B., Royer, B, Grosbois, B., Jaubert, J., Preux, Pierre-Marie, Cogné, Michel, J.P., Fermand, Grelier, Elisabeth, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), Laboratoire de Biostatistique et d'Informatique Médicale, and Université de Limoges (UNILIM)

Subjects
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2005

82. Une lésion d’évolution initialement indolente puis fulminante

Author

Hardy, J.M., primary, Paul, C., additional, Pauwels, C., additional, Lamant, L., additional, Viraben, R., additional, Hautier-Mazereeuw, J., additional, Meyer, N., additional, Alberto, C., additional, Serano, E., additional, Oberic, L., additional, Ysebaert, L., additional, Recher, C., additional, and Bulai Livideanu, C., additional

Published
2014
Full Text
View/download PDF

83. 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

Author

Stathis, A., primary, Quesnel, B., additional, Amorim, S., additional, Thieblemont, C., additional, Zucca, E., additional, Raffoux, E., additional, Dombret, H., additional, Peng, Y., additional, Palumbo, A., additional, Vey, N., additional, Thomas, X., additional, Michallet, M., additional, Gomez-Roca, C., additional, Recher, C., additional, Karlin, L., additional, Yee, K., additional, Rezai, K., additional, Preudhomme, C., additional, Facon, T., additional, and Herait, P., additional

Published
2014
Full Text
View/download PDF

91. Cas groupes d’infections fongiques invasives à Geotrichum clavatum dans le sud ouest de la France

Author

Chauvin, P., primary, Picard, M., additional, Verdeil, X., additional, Recher, C., additional, Iriart, X., additional, Cavaille, L., additional, Huguet, F., additional, Bouvet, E., additional, Desnos, M., additional, Arnaud, S., additional, Valentin, A., additional, Marchou, B., additional, Ruiz, J., additional, Fillaux, J., additional, Roques, C., additional, Petit., J., additional, Masson, R., additional, Gaschet, A., additional, Sanhes, L., additional, Miquel, C., additional, Berry, A., additional, and Cassaing, S., additional

Published
2013
Full Text
View/download PDF

92. Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis.

Author

Bulai Livideanu, C., Apoil, P. A., Lepage, B., Eischen, M., Laurent, C., Laharrague, P., Lamant, L., Tournier, E., Tavitian, S., Pouplard, C., Recher, C., Laroche, M., Mailhol, C., Dubreuil, P., Hermine, O., Blancher, A., and Paul, C.

Subjects
MAST cell disease, BONE marrow, TRYPTASE, CONFIDENCE intervals
Abstract

Background Mastocytosis is difficult to diagnose, especially when systemic mast cell activation symptoms are not present or involve only one extracutaneous organ. Objective The main objective was to evaluate the accuracy of the bone marrow tryptase level in the diagnosis of systemic mastocytosis in patients with a clinical suspicion of mastocytosis. Methods We included all adult patients evaluated in our centre between December 2009 and 2013 for suspected mastocytosis as part of a standardized procedure and who had a bone marrow and serum tryptase assay on the same day. The diagnosis of systemic mastocytosis was established on the basis of the World Health Organization criteria as the gold standard. The accuracy of the bone marrow tryptase level in the diagnosis of systemic mastocytosis was assessed by a receiver operating characteristics curve analysis. The different sensitivity and specificity values, corresponding to the set of possible bone marrow tryptase level cut-off values, were estimated with 95% confidence intervals. Results Seventy-three patients were included. The diagnosis of systemic mastocytosis wasestablished in 43 patients (58.9%). The median bone marrow tryptase level was 423 lg/L[95% CI: 217-868] in the systemic mastocytosis group and 7.5 μg/L [95% CI: 4.6-17.1] inthe non-systemic mastocytosis group (P < 0.001). A cut-off value of 50 μg/L for bonemarrow tryptase identified systemic mastocytosis with a sensitivity of 93.0% [95% CI: 80.9-98.5%] and a specificity of 90.0% [95% CI: 73.5-97.9%]. Conclusion and Clinical Relevance The bone marrow tryptase level appears to be a valuable diagnostic criterion for confirming systemic mastocytosis. If this diagnosis can reliably be excluded by evaluation of the bone marrow tryptase level, there would be no need to perform a bone marrow biopsy. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

93. Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-Cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: Preliminary results of the LNH03-6B randomized GELA study.

Author

UCL - Autre, Delarue, R., Mounier, N., Haioun, C., Coiffier, B., Gisselbrecht, C., Ghesquieres, H., Lederlin, P., Blanc, M., Recher, C., Hermine, O., Reyes, F., Tilly, H., Bosly, André, UCL - Autre, Delarue, R., Mounier, N., Haioun, C., Coiffier, B., Gisselbrecht, C., Ghesquieres, H., Lederlin, P., Blanc, M., Recher, C., Hermine, O., Reyes, F., Tilly, H., and Bosly, André

Published
2006

98. Subsequent Hematopoietic Stem Cell Transplantation (HSCT) Associated with Longer Survival in Patients with Relapsed/Refractory (R/R) Acute Myelogenous Leukemia (AML) After Clo+Ara-C or Ara-C Alone: A Landmark Analysis from the Classic I Trial

Author

Ganguly, S., primary, Kantarjian, H.M., additional, Wetzler, M., additional, Rizzieri, D., additional, Schiller, G., additional, Hagasia, M., additional, Stuart, R., additional, Avigan, D., additional, Craig, M., additional, Collins, R., additional, Maris, M., additional, Kovacsovics, T., additional, Golberg, S., additional, Seiter, K., additional, Hari, P., additional, Greiner, J., additional, Vey, N., additional, Recher, C., additional, Ravandi, F., additional, Wang, E., additional, Eckert, S., additional, Partisano, A., additional, and Faderl, S., additional

Published
2012
Full Text
View/download PDF

99. Rituximab given after high dose therapy and autologous stem cell transplantation induces durable clearance of minimal residual disease in about half of the patients with follicular non Hodgkin's lymphoma: 36 months results of a multicenter open label phase II trial (M39012 trial).

Author

UCL - Autre, Morschhauser, F., Recher, C., Milpied, N., Gressin, R, Salles, G., Brice, P., Vey, N, Haioun, C., Colombat, P, Bourhis, JH, Rossi, JF, Berriot-Varoqueaux, N, Bergougnoux, L, Bosly, André, Delsol, G., Attal, M., 46th Annual Meeting of the American-Society-of-Hematology, UCL - Autre, Morschhauser, F., Recher, C., Milpied, N., Gressin, R, Salles, G., Brice, P., Vey, N, Haioun, C., Colombat, P, Bourhis, JH, Rossi, JF, Berriot-Varoqueaux, N, Bergougnoux, L, Bosly, André, Delsol, G., Attal, M., and 46th Annual Meeting of the American-Society-of-Hematology

Published
2004

100. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study

Author

Vergez, F., primary, Green, A. S., additional, Tamburini, J., additional, Sarry, J.-E., additional, Gaillard, B., additional, Cornillet-Lefebvre, P., additional, Pannetier, M., additional, Neyret, A., additional, Chapuis, N., additional, Ifrah, N., additional, Dreyfus, F., additional, Manenti, S., additional, Demur, C., additional, Delabesse, E., additional, Lacombe, C., additional, Mayeux, P., additional, Bouscary, D., additional, Recher, C., additional, and Bardet, V., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results